Adverse Events Associated with Radium-223: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization

被引：0
|
作者：
Huynh-Le, M. P. [1 ]
Shults, R. C. [1 ]
Connor, M. [1 ]
Hattangadi-Gluth, J. A. [1 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.1315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3298
引用
收藏
页码：E562 / E562
页数：1
相关论文
共 50 条
  • [11] PAIN AND ARTHRALGIA ADVERSE EVENTS ASSOCIATED WITH CRIZANLIZUMAB AND VOXELOTOR: DISPROPORTIONALITY ANALYSIS OF US FDA ADVERSE EVENTS REPORTING SYSTEM (FAERS)
    Ologunowa, A.
    Caffrey, A. R.
    VALUE IN HEALTH, 2023, 26 (06) : S208 - S208
  • [12] Clinical practice patterns of Radium-223 (R223) utilization and variables associated with completion of therapy.
    Taplin, Mary-Ellen
    Jacobus, Susanna J.
    Fiorillo, Matthew
    Ledet, Elisa M.
    Cotogno, Patrick
    Steinberger, Allie E.
    Jacene, Heather A.
    Sartor, Oliver
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [13] A disproportionality analysis of FDA adverse event reporting system events for misoprostol
    Yang, Li
    Xu, Wenting
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [14] Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Dai, Zhicheng
    Zhang, Jiafeng
    Tao, Zhengbo
    Gao, Rui
    Zhao, Qinghua
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [15] Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
    Lin, Shan
    Luo, Dachen
    Gong, Zonglian
    Zhan, Qingyuan
    FRONTIERS IN MEDICINE, 2024, 11
  • [16] Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
    Ding, Lingqing
    Chen, Congqin
    Yang, Yongkuan
    Fang, Jie
    Cao, Longxing
    Liu, Yige
    CARDIOVASCULAR THERAPEUTICS, 2022, 2022
  • [17] Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
    Guo, Haoning
    Wang, Bin
    Yuan, Shuying
    Wu, Silin
    Liu, Jing
    He, Miaoquan
    Wang, Jisheng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [18] Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system
    Du, Yikuan
    Zhang, Mengting
    Chen, Mianhai
    Hu, Mianda
    Zeng, Wenqi
    Cai, Xiaolin
    Zhang, Weichui
    Zhu, Jinfeng
    Zhong, Mingjun
    Liu, Yi
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [19] A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
    Pan, Yunyan
    Wang, Yu
    Zheng, Yifan
    Chen, Jie
    Li, Jia
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [20] DISPROPORTIONALITY ANALYSIS FOR PHARMACOVIGILANCE OF MEDICAL DEVICE RELATED ADVERSE EVENTS REPORTED TO THE FDA
    Duggirala, H. J.
    Herz, N. D.
    Canos, D. A.
    Sullivan, R.
    Schaaf, Richard
    Pinnow, E.
    Marinac-Dabic, D.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S131 - S131
12345